Axovant to pull plug on Alzheimer's drug after key study fails

(Reuters) - Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer's after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.